z-logo
open-access-imgOpen Access
Aumolertinib challenge as an optional treatment in advanced non small‑cell lung cancer after osimertinib failure with epidermal growth factor receptor‑sensitive mutation: A case series
Author(s) -
Xinjing Ding,
Jianghua Ding,
Zhaohui Leng,
Yun Song
Publication year - 2022
Publication title -
oncology letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.766
H-Index - 54
eISSN - 1792-1082
pISSN - 1792-1074
DOI - 10.3892/ol.2022.13520
Subject(s) - osimertinib , epidermal growth factor receptor , molecular medicine , cancer research , a431 cells , oncogene , lung cancer , cell cycle , epidermal growth factor , cancer , medicine , oncology , biology , receptor , erlotinib

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here